CLINICAL TRIALS PROFILE FOR ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
✉ Email this page to a colleague
All Clinical Trials for albuterol sulfate; ipratropium bromide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00462540 ↗ | A Crossover Study in the Treatment of Patients With COPD | Completed | Dey | Phase 3 | 2007-05-01 | The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI |
| NCT01515995 ↗ | Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation | Completed | University of Texas Southwestern Medical Center | Phase 4 | 2012-01-01 | The purpose of this study is to evaluate the effectiveness of nebulized magnesium sulfate as a vehicle for albuterol in children with moderate to severe asthma exacerbation. |
| NCT02182674 ↗ | A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Completed | Boehringer Ingelheim | Phase 2 | 2000-10-01 | Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two puffs of the marketed chlorofluorocarbon (CFC) containing product, Combivent (CFC) inhalation aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff). The dose response profile, safety and pharmacokinetics of Combivent HFA formulation are to be characterized. |
| NCT02586649 ↗ | 24hr Effects of Tiotropium Bromide in Tetraplegia | Completed | James J. Peters Veterans Affairs Medical Center | Phase 2 | 2014-07-01 | Respiratory complications are the leading cause of death during the initial year after acute SCI, and the third leading cause of death thereafter. Complete or partial loss of respiratory muscle innervations in individuals with cervical and high thoracic injuries leads to inadequate ventilation and inability to effectively clear secretions, often prompting supportive ventilation following initial injury. Development of atelactasis, pneumonias and respiratory failure are the most common respiratory complications observed during the acute phase of injury. It is well known that a restrictive ventilatory defect, dependent upon the level and completeness of injury, is apparent in individuals with chronic cervical SCI. Respiratory functional impairment might be further compromised in these individuals, the majority of whom share many aspects of obstructive airway physiology commonly associated with asthma. The asthma-like features that individuals with chronic cervical SCI demonstrate have been hypothesized to be due to overriding cholinergic airway tone carried by intact vagal (parasympathetic) nerve fibers arising from the brainstem, whereas sympathetic innervations is interrupted at the level of the upper thoracic spinal cord. Whether airway narrowing and AHR in chronic cervical SCI is also related to chronic airway inflammation is unknown, although it is conceivable that repeated respiratory infections or, possibly, a neurogenic component, could contribute to chronic airway inflammation. Therefore, the investigators aim to assess how long-acting bronchodilator (tiotropium bromide) affects various indices of lung function, including: pulmonary function tests, levels of inflammation and cough strength across 24 hours after receiving study drug. Results will be analyzed for baseline, 1 hour, 3 hours, 20 hours and 24 hours post drug inhalation for both active medication and non-active placebo. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for albuterol sulfate; ipratropium bromide
Condition Name
Condition MeSH
Clinical Trial Locations for albuterol sulfate; ipratropium bromide
Trials by Country
Clinical Trial Progress for albuterol sulfate; ipratropium bromide
Clinical Trial Phase
Clinical Trial Sponsors for albuterol sulfate; ipratropium bromide
Sponsor Name
